Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and SABR in metastatic NSCLC
NCT03307759Phase 1Terminated
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Dec 2017
- Primary completion
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Peter MacCallum Cancer Centre. Started Dec 2017; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03307759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03307759.